I agree. Too much uncertainty in short- and long-term efficacy. And the optics of changing the plan now, for a regimen that hasn’t been tested directly, are not great. Follow on studies can assess non-inferiority of a one dose regimen, but for now the data support two doses.
-
-
I think the medical profession (not addressing you guys at all!) really conflates these. They assume we can't tell people about uncertainty and trade-offs and then we end up in suboptimal positions, but we don't even get the trust because complexity/uncertainty isn't the problem.
-
My guess is that if we had prelim data & asked for volunteers in non high-risk groups (for example, HCW: risk by exposure status not age), we'd be surprised by the update. The public can absolutely follow discussions of trade-offs under uncertainty if it's truly transparent.
- Show replies
New conversation -
-
-
I would definitely support asking for volunteers among lower-risk people in high priority groups, to do a single dose trial asap.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.